KALA BIO director David Lazar resigns

KALA BIO, Inc. reported that on February 16, 2026, director David Lazar resigned from the company’s Board of Directors, effective the same day.

Rhea-AI Filing Summary

KALA BIO, Inc. reported that on February 16, 2026, director David Lazar resigned from the company’s Board of Directors, effective the same day. The company stated that Mr. Lazar’s resignation was not related to any disagreement with KALA BIO regarding its operations, policies, or practices. The filing is a governance update and does not describe any accompanying strategic or financial changes.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did KALA (KALA BIO, Inc.) disclose in this 8-K?

KALA BIO disclosed that director David Lazar resigned from its Board of Directors effective February 16, 2026. The company described this as a board-level change without detailing any related strategic or operational shifts.

Did KALA BIO say David Lazar disagreed with the company before resigning?

KALA BIO stated that David Lazar’s resignation was not related to any disagreement with the company on its operations, policies, or practices. This language suggests the departure was not due to a disclosed dispute.

When did David Lazar’s resignation from KALA BIO’s board become effective?

David Lazar’s resignation from the KALA BIO Board of Directors became effective on February 16, 2026. The notice of his decision and the effective date are the same in the disclosure.

Who signed the KALA BIO 8-K reporting David Lazar’s resignation?

The 8-K was signed on behalf of KALA BIO by Avi Minkowitz, the company’s Chief Executive Officer, dated February 20, 2026, fulfilling the company’s reporting obligations under the Securities Exchange Act of 1934.

Does KALA BIO’s 8-K mention any changes to its operations with this board resignation?

The 8-K mentions only David Lazar’s resignation from the Board and confirms no disagreement on operations, policies, or practices. It does not describe any direct changes to KALA BIO’s operations or strategy linked to this event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:05 PM EST Learn about SEC filing dates

false 0001479419 0001479419 2026-02-16 2026-02-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2026

KALA BIO, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-38150		27-0604595
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1167 Massachusetts Avenue

Arlington, MA 02476

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 996-5252

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On February 16, 2026, David Lazar notified KALA BIO, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective as of the same date. Mr. Lazar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KALA BIO, INC.
February 20, 2026	By:	/s/ Avi Minkowitz
		Name:	Avi Minkowitz
		Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB